VRTX
Vertex Pharmaceuticals·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 5
Bearish signal 1
Ample Liquidity
High Gross Profit Margin
High Cash/net Profit Ratio
Revenue Beats Expectation
EPS Beats Expectation
RSI Overbought
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About VRTX
Vertex Pharmaceuticals Incorporated
A company that develops therapies for the treatment of cystic fibrosis
50 Northern Avenue, Boston, Massachusetts 02210
Develop and create transformative drugs
Founded in 1989, Vertex Pharmaceuticals Incorporated is a global biotechnology company. The company is dedicated to the discovery, development, production and commercialization of small molecule drugs for serious diseases in the professional market. The company has partnerships with some of the world's largest pharmaceutical companies, leading non-profit disease research institutions, and many of the world's most renowned academic institutions. The company has two products: KALYDECO and INCIVEK.
Earnings Call
Q1/2025
Estimate EPS4.29
Actual EPS4.06
Estimate Revenue2.86B
Actual Revenue2.77B
Vertex Pharmaceuticals Q1 2025: Unraveling Contradictions in JOURNAVX Launch, CASGEVY Revenue, and ALYTREK Uptake
May 06,2025 07:34
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS4.25
Actual EPS4.52
Estimate Revenue2.91B
Actual Revenue2.96B
Vertex Pharmaceuticals' Q2 2025: Unpacking Contradictions in JOURNAVX Strategy, Trial Timelines, and Market Dynamics
Aug 04,2025 09:37
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
VRTX has released its 2025 Q3 earnings. EPS was reported at 4.8, versus the expected 4.58, beating expectations. The chart below visualizes how VRTX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
VRTX has released its 2025 Q3 earnings report, with revenue of 3.08B, reflecting a YoY change of 10.99%, and net profit of 1.08B, showing a YoY change of 3.59%. The Sankey diagram below clearly presents VRTX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
